Related Experiment Video

Updated: May 4, 2026

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
09:16

Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR

Published on: February 5, 2018

6.2K

Research progress regarding CYP3A gene family in gastric cancer

Qi Jia1, Qingsong Ding2, Kangmei Shao2

  • 1Second Clinical Medical School, Lanzhou University, Lanzhou 730030. 1223684838@qq.com.

Zhong Nan Da Xue Xue Bao. Yi Xue Ban = Journal of Central South University. Medical Sciences
|March 6, 2024
PubMed

Insights

Cytochrome P450 family 3 subfamily A (CYP3A) enzymes are crucial for drug metabolism and are overexpressed in tumors. Targeting CYP3A offers new strategies for gastric cancer diagnosis and treatment.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Oncology

Background:

  • Cytochrome P450 family 3 subfamily A (CYP3A) is a critical drug-metabolizing enzyme system in humans.
  • CYP3A enzymes are involved in approximately 60% of drug metabolism and are found in both normal and tumor tissues.
  • Aberrant CYP3A expression is implicated in gastric cancer development and chemotherapeutic drug resistance.

Purpose of the Study:

  • To highlight the significance of CYP3A in drug metabolism and its role in gastric cancer.
  • To explore the potential of targeting CYP3A for novel gastric cancer therapeutic strategies.

Main Methods:

  • Literature review and analysis of existing research on CYP3A function and its involvement in gastric cancer.
  • Examination of the role of CYP3A in drug metabolism, gastric carcinogenesis, and chemoresistance.

Main Results:

  • CYP3A enzymes are widely distributed and significantly overexpressed in various tumor tissues, including gastric cancer.
  • CYP3A plays a role in the progression of chronic atrophic gastritis to gastric cancer.
  • CYP3A influences the differential metabolism and resistance of chemotherapeutic agents.

Conclusions:

  • Targeting CYP3A-mediated prodrugs presents a promising new approach for gastric cancer treatment.
  • CYP3A is a potential target for the diagnosis and treatment of gastric cancer.
Keywords:
cytochrome P450cytochrome P450 3Acytochrome P450 3A4drug metabolizing enzymesgastric cancertumor

More Related Videos

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

5.6K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

701

Related Concept Videos

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121